Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Short-term Investments (2016 - 2025)

Syndax Pharmaceuticals (SNDX) has 11 years of Short-term Investments data on record, last reported at $19.6 million in Q4 2025.

  • For Q4 2025, Short-term Investments rose 95.59% year-over-year to $19.6 million; the TTM value through Dec 2025 reached $19.6 million, up 95.59%, while the annual FY2025 figure was $19.6 million, 95.59% up from the prior year.
  • Short-term Investments reached $19.6 million in Q4 2025 per SNDX's latest filing, down from $319.2 million in the prior quarter.
  • Across five years, Short-term Investments topped out at $346.6 million in Q2 2025 and bottomed at $115000.0 in Q4 2021.
  • Average Short-term Investments over 5 years is $123.0 million, with a median of $10.0 million recorded in 2024.
  • Peak YoY movement for Short-term Investments: tumbled 94.29% in 2021, then soared 7373.91% in 2022.
  • A 5-year view of Short-term Investments shows it stood at $115000.0 in 2021, then skyrocketed by 7373.91% to $8.6 million in 2022, then dropped by 19.9% to $6.9 million in 2023, then surged by 45.66% to $10.0 million in 2024, then soared by 95.59% to $19.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Short-term Investments were $19.6 million in Q4 2025, $319.2 million in Q3 2025, and $346.6 million in Q2 2025.